Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYLO DUAL is a sterile, preservative-free ophthalmic solution containing sodium hyaluronate and ectoine. Developed by URSAPHARM Arzneimittel and distributed in China by Shenzhen Relin Medicine, it is indicated for the lubrication of dry eyes and the relief of symptoms associated with allergic reactions, such as itching and burning. Sodium hyaluronate acts as a lubricant by increasing the viscosity of the tear film, while ectoine is a natural extremolyte that forms a protective water shell around molecules, stabilizing the lipid layer of the tear film and protecting the ocular surface against environmental allergens and inflammatory triggers. The product is often regulated as a medical device due to its primary physical mode of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + ectoine.